Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland.
Pirjo Pietinen(Institute for Molecular Medicine Finland), Herman Adlercreutz(University of Helsinki), Satu Männistö(Finnish Institute for Health and Welfare), Matti Uusitupa(University of Eastern Finland), Vesa Kataja(Kuopio University Hospital), Karl Stumpf
PubMed
April 1, 2001
Cited by 246
Related Papers
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
|Annals of Oncology|2014|1.3k
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2010|600
A recurrent mutation in PALB2 in Finnish cancer families
|Nature|2007|461